Patterns of Disease Progression in Advanced Breast Cancer Patients Treated With Cyclin D Kinase 4/6 Inhibitors: Prognostic and Therapeutic Implications.
[INTRODUCTION] To study the patterns of progression (POP) in hormone receptor-positive (HR+), human epidermal growth receptor 2-negative (HER2-) advanced breast cancer (aBC) treated with cyclin D kina
- p-value P = .01
- p-value P = .02
APA
Kumar S, Pathak N, Pezo RC (2026). Patterns of Disease Progression in Advanced Breast Cancer Patients Treated With Cyclin D Kinase 4/6 Inhibitors: Prognostic and Therapeutic Implications.. Clinical breast cancer, 26(5), 91-99. https://doi.org/10.1016/j.clbc.2026.04.001
MLA
Kumar S, et al.. "Patterns of Disease Progression in Advanced Breast Cancer Patients Treated With Cyclin D Kinase 4/6 Inhibitors: Prognostic and Therapeutic Implications.." Clinical breast cancer, vol. 26, no. 5, 2026, pp. 91-99.
PMID
42035712
Abstract
[INTRODUCTION] To study the patterns of progression (POP) in hormone receptor-positive (HR+), human epidermal growth receptor 2-negative (HER2-) advanced breast cancer (aBC) treated with cyclin D kinase inhibitor (CDK 4/6i) and analyze their impact on prognosis and subsequent treatment.
[PATIENTS AND METHODS] We retrospectively investigated patients with HR+ HER2- aBC with progressive disease after CDK4/6i treatment at our center from 2016 to 2020. Based on European Society for Radiotherapy and Oncology (ESTRO)/European Organization for Research and Treatment of Cancer (EORTC) consensus, patients were divided into 4 groups: repeat oligoprogression (RO, oligoprogression with a history of oligometastatic disease), induced oligoprogression (IO, oligoprogression with a history of polymetastatic disease), collectively oligoprogressive disease (OPD), de novo polyprogression (DP, polyprogression with a history of oligometastatic disease), and repeat polyprogression (RP, polyprogression with a history of polymetastatic disease)-together diffusely progressive disease (DPD). Kaplan-Meier survival analysis was used for time-to-event data.
[RESULTS] Among the 151 patients, 47 (31%) had OPD, including 33 (22%) with RO and 13 (9%) with IO. Similarly, 104 (69%) patients had DPD, including 93 (61%) with RP and 12 (8%) with DP. The 1-year next-line progression-free survival (nPFS) was 60.5% in the IO group, 42.9% in the RO group, 30.3% in the DP group, and 26% in the RP group (P = .01). The 3-year overall survival (OS) was also significantly different (84% vs. 79% vs. 66% vs. 39%, P = .02). The continuation of CDK4/6i beyond oligoprogression did not lead to worse outcomes (6-month nPFS, 69.9% vs. 73.7%, P = .07).
[CONCLUSION] The 4 distinct POP after CDK 4/6i treatment have prognostic value, and in this small but relevant cohort of patients, continuation of CDK 4/6i appears to be safe in those with IO.
[PATIENTS AND METHODS] We retrospectively investigated patients with HR+ HER2- aBC with progressive disease after CDK4/6i treatment at our center from 2016 to 2020. Based on European Society for Radiotherapy and Oncology (ESTRO)/European Organization for Research and Treatment of Cancer (EORTC) consensus, patients were divided into 4 groups: repeat oligoprogression (RO, oligoprogression with a history of oligometastatic disease), induced oligoprogression (IO, oligoprogression with a history of polymetastatic disease), collectively oligoprogressive disease (OPD), de novo polyprogression (DP, polyprogression with a history of oligometastatic disease), and repeat polyprogression (RP, polyprogression with a history of polymetastatic disease)-together diffusely progressive disease (DPD). Kaplan-Meier survival analysis was used for time-to-event data.
[RESULTS] Among the 151 patients, 47 (31%) had OPD, including 33 (22%) with RO and 13 (9%) with IO. Similarly, 104 (69%) patients had DPD, including 93 (61%) with RP and 12 (8%) with DP. The 1-year next-line progression-free survival (nPFS) was 60.5% in the IO group, 42.9% in the RO group, 30.3% in the DP group, and 26% in the RP group (P = .01). The 3-year overall survival (OS) was also significantly different (84% vs. 79% vs. 66% vs. 39%, P = .02). The continuation of CDK4/6i beyond oligoprogression did not lead to worse outcomes (6-month nPFS, 69.9% vs. 73.7%, P = .07).
[CONCLUSION] The 4 distinct POP after CDK 4/6i treatment have prognostic value, and in this small but relevant cohort of patients, continuation of CDK 4/6i appears to be safe in those with IO.
같은 제1저자의 인용 많은 논문 (5)
- Proteasome Assembly Chaperone 3 Defines Metabolic-Immune Programs and Poor Prognosis in Breast Cancer via Multi-Omics Approaches.
- Molecular heterogeneity of Glioblastoma-associated microglia and macrophages and myeloid-derived suppressor cells: Insights from single-cell omics and therapeutic implications.
- Comment on «Comparing Prostatype® P-score and traditional risk models for predicting prostate cancer outcomes in Spain».
- Exploring vulnerable building blocks in protein-protein interaction networks of breast tumor and adjacent normal tissues.
- Point-of-Care CagA Antibody Positivity and Its Association with Precancerous Gastric Changes.